Martijn Cox
Co-Founder
Xeltis
Xeltis is developing artificial vascular implants that are gradually replaced by the patient's own living tissue, utilizing their proprietary Endogenous Tissue Restoration (ETR) technology. This approach reduces the risks of thrombosis, stenosis, and infection associated with traditional vascular surgeries, improving patient outcomes and minimizing the need for surgical reinterventions.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$13.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional vascular surgeries often involve artificial implants that carry risks of thrombosis, stenosis, calcification, and infection, potentially leading to implant failure and the need for surgical reinterventions. Current vascular replacement options may not fully integrate with the patient's own tissue, leading to complications and limiting long-term performance.
Solution
Xeltis is developing a novel class of vascular and valve implants based on its proprietary Endogenous Tissue Restoration (ETR) platform. These implants are designed to enable the patient's own body to naturally restore a new, living blood vessel or valve. The ETR process utilizes supramolecular chemistry and electrospun nanofibers to create a scaffold that facilitates tissue ingrowth and regeneration. Over time, the artificial implant is gradually replaced by the patient's own healthy tissue, reducing the risk of complications associated with traditional implants. This approach aims to provide self-healing, non-immunogenic implants that remain open, with low infection risk, and reduced need for surgical reintervention.
Target Audience
The primary target audience includes vascular surgeons, interventional cardiologists, and patients undergoing vascular or valve replacement procedures, particularly those requiring hemodialysis access or coronary artery bypass surgery.
Features
- Endogenous Tissue Restoration (ETR) platform that enables natural tissue regeneration
- Supramolecular chemistry and electrospinning to create nanofiber-based implants
- Implants designed to be gradually replaced by the patient's own living tissue
- Low infection rates and no occurrence of narrowing or stenosis observed in research
- Reduced need for reinterventions compared to existing treatments
- Scalable and easy to store implants
- Compatible with standard surgical techniques
- aXess conduit for hemodialysis vascular access
- XABG device for coronary artery bypass grafting (CABG)